First quarter 2025 revenue of $40.8 million 45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-year Operationalized $10 million more in annual run rate cost reductions, ...
Achieved multiple critical milestones for development of the South West Arkansas (“SWA”) Project Steadily progressing towards a Final Investment Decision for Phase 1 of SWA targeted by year-end 2025 ...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results